Covid-19 Pediatric Observatory
PANDOR
1 other identifier
observational
5,000
1 country
76
Brief Summary
In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei Province in the People's Republic of China. The disease spreads rapidly and the number of sick people is increasing. On January 3, 2020 a new virus of the coronavirus family is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhan and subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the World Health Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On 11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus 2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is a pandemic. As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with more than 16,000 deaths attributed to this virus. (Ref WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ). In France, the number of cases rose from 105 cases at the end of February to 19615 confirmed cases on March 24. (Source Public Health France). Most of the cases are adults. However, children are not completely spared and serious cases have been described. These severe cases can be respiratory or extra-respiratory (e.g. myocarditis). We also know that pediatric and adult cases differ in terms of clinical, biological and imaging findings, particularly chest CT scans. However, the description of paediatric pictures, especially severe forms and the involvement of children suffering from co-morbidities, remains poorly reported. Finally, the risk factors for serious cases in children remain largely unknown. This observatory aim to describe the clinical phenotypes of hospitalized pediatric patients with Covid19 in France, according to age groups. Moreover for a subgroup of patients, informations regarding the long covid will be reported.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Longer than P75 for all trials
76 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 30, 2020
CompletedFirst Posted
Study publicly available on registry
April 7, 2020
CompletedStudy Start
First participant enrolled
April 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedNovember 25, 2022
November 1, 2022
4.2 years
March 30, 2020
November 21, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of children with severe or critical form.
Day 14
Secondary Outcomes (13)
Percentage of children requiring intensive care support
at admission
Percentage of children requiring intensive care support
at day 14
Clinical symptoms of children
at admission
Clinical symptoms of children
day 14
Biological results of children
at admission
- +8 more secondary outcomes
Study Arms (1)
hospitalized children with Covid19
\- Children \< 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
Interventions
All patients under 18 years hospitalized with a covid19 diagnosis
Eligibility Criteria
children hospitalized with covid19
You may qualify if:
- Children \< 18 years old
- Admitted in French pediatric wards
- With a confirmed COVID-19 infection. ( on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
You may not qualify if:
- Expressed refusal to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (76)
Chu Felix Guyon
Saint-Denis, La Réunion, France
Ch St Esprit
Agen, France
Ch General Aix En Provence -
Aix-en-Provence, France
CHU Angers
Angers, France
CH d'ANGOULEME
Angoulème, France
Pringy - Ch D'Annecy
Annecy, France
CH Argenteuil
Argenteuil, France
Ch Armentieres
Armentières, France
CH Arpajon
Arpajon, France
Ch Auxerre
Auxerre, France
CH GENERAL Henri Duffaut
Avignon, France
CHU de BESANCON
Besançon, France
Hopital Femme Enfant
Caen, France
Ch de Pontoise
Cergy-Pontoise, France
Ch W. Morey
Chalon-sur-Saône, France
CH de CHAMBERY
Chambéry, France
Ch Hotel Dieu
Chartres, France
CHU Estaing
Clermont-Ferrand, France
Hopital Louis Pasteur
Colmar, France
Hopital Louis Mourrier
Colombes, France
CH Sud Francilien
Corbeil-Essonnes, France
Centre Hospitalier intercommunal de Creteil
Créteil, 94010, France
Ch de Dax
Dax, France
Hopital D'Enfants Chu Dijon
Dijon, France
CH Louviers Val de Reuil
Elbeuf, France
CH Jean Monnet
Épinal, France
CH Gonesse
Gonesse, France
CH d'HYERES
Hyères, France
Ch de Marne La Vallee
Jossigny, France
Chru de Grenoble
La Tronche, France
CHGénéral du HAVRE
Le Havre, France
Hopital Jeanne de Flandre
Lille, France
Hopital Roger Salengro - Lille
Lille, France
Hopital Saint Vincent de Paul
Lille, France
Ch de Longjumeau
Longjumeau, France
Lorient - Ch de Bretagne Sud
Lorient, France
Hopital Femme Mere Enfant-Bron
Lyon, France
Hopital de Mantes
Mantes-la-Jolie, France
Hopital Nord Enfants
Marseille, France
Hopital de Meaux
Meaux, France
Ch de Melun
Meulin, France
CH de Montargis
Montargis, France
CH de MONTBRISON
Montbrison, France
Hopital Arnaud de Villeneuve
Montpellier, France
CHRU de Nancy
Nancy, France
Nantes - Hopital Mere Enfant
Nantes, France
Ch de Neuilly Sur Seine
Neuilly-sur-Seine, France
Hopital Lenval
Nice, France
CHU Nimes Caremeau
Nîmes, France
Chr Orleans
Orléans, France
Assistance Publique Hôpitaux de Paris
Paris, 75004, France
Hopital St Jean Roussillon
Perpignan, France
POISSY - CH de POISSY
Poissy, France
QUIMPER - CH de Cornouaille
Quimper, France
RANG du FLIERS - C.H.A.M.
Rang-du-Fliers, France
Hopital Américain CHU REIMS
Reims, France
CH RODEZ
Rodez, France
CH de ROMANS
Romans-sur-Isère, France
Chu Rouen
Rouen, France
Hopital Charles-Nicolle
Rouen, France
Ch de Saint Denis
Saint-Denis, France
Chu St Etienne
Saint-Etienne, France
Ch Du Pays Du Mont Blanc
Sallanches, France
Chg Salon de Provence
Salon-de-Provence, France
Ch de Saint Malo
St-Malo, France
CH Hautepierre
Strasbourg, France
CH Tarbes
Tarbes, France
CH Bel Air
Thionville, France
Hopital Sainte Musse
Toulon, France
CHU Toulouse-hôpital des Enfants
Toulouse, France
Hôpital Gatien De Clocheville
Tours, France
Hôpital Nord Franche-Comté
Trévenans, France
CH de TROYES
Troyes, France
Ch Bretagne Atlantique
Vannes, France
Ch Le Chesnay
Versailles, France
Hopital de Villeneuve Saint Georges
Villeneuve-Saint-Georges, France
Related Publications (1)
Rybak A, Ouldali N, Werner A, Casha P, Robert B, de Pontual L, Bechet S, Cahn-Sellem F, Angoulvant F, Cohen R, Levy C; PANDOR study group. Characteristics of Children Hospitalized for Acute COVID-19 in France From February 2020 to December 2023. Pediatr Infect Dis J. 2025 Apr 1;44(4):346-350. doi: 10.1097/INF.0000000000004681. Epub 2025 Feb 14.
PMID: 39961110DERIVED
Related Links
- Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children
- Factors Associated With Severe SARS-CoV-2 Infection
- Educational Setting and SARS-CoV-2 Transmission Among Children With Multisystem Inflammatory Syndrome: A French National Surveillance System
- Analysis of COVID-19 Vaccination Status Among Parents of Hospitalized Children Younger Than 5 Years With SARS-CoV-2 Infection During the Delta and Omicron Waves
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 30, 2020
First Posted
April 7, 2020
Study Start
April 7, 2020
Primary Completion
June 30, 2024
Study Completion
June 30, 2024
Last Updated
November 25, 2022
Record last verified: 2022-11
Data Sharing
- IPD Sharing
- Will not share